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Background: Human cytomegalovirus (CMV) has been detected in the thyroid gland and thyroid tumors. CMV
infection may activate the mitogen-activated protein kinase pathway, of which aberrant activation is frequently
associated with BRAF mutation in papillary thyroid cancer.
Methods: A total of 45 paired tumorous and adjacent non-neoplastic tissue samples, including 5 follicular adenoma
and 40 papillary thyroid cancer, were obtained during thyroidectomy. BRAF mutational status was determined using
direct sequencing. The presence of CMV DNA was determined using conventional PCR and quantitative real-time
PCR. CMV protein in the tissue samples were evaluated with Western blot analysis.
Results: BRAF mutation was identified in the cancerous part of 31 (78%) papillary thyroid cancers. Papillary cancer
with BRAF mutation was significantly associated with a larger tumor size (P = 0.045), extrathyroidal invasion
(P = 0.012), lymph node metastasis (P = 0.008), and a higher TNM stage (P = 0.044). CMV DNA and protein were
not detected in any studied samples.
Conclusions: Our results suggest no association between CMV infection and papillary thyroid cancer.
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Differentiated thyroid cancer arising from the follicular
epithelium is the most common endocrine malignancy,
and papillary thyroid cancer accounts for the majority of
differentiated thyroid cancers [1]. Given the fact that the
prevalence of familial non-medullary thyroid cancer is
only about 5% [2], differentiated thyroid cancer is mostly
sporadic. The only established epidemiological factors in
association with thyroid cancer are ionizing radiation
and iodine deficiency [3]. Nonetheless, most patients di-
agnosed to have thyroid cancer do not have these predis-
posing factors. Therefore, the mechanisms underlying
thyroid cancer development are still poorly defined.
Many genetic and epigenetic alterations have been im-
plicated in the pathogenesis of thyroid cancer. The v-raf* Correspondence: surg.mmh@gmail.com
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tation is the most common genetic alteration in papillary
thyroid cancer [1]. BRAF activates the mitogen-activated
protein kinase (MAPK) pathway and plays an important role
in regulating cellular differentiation, proliferation, and sur-
vival [4]. Oncogenic BRAF may trigger a proinflammatory
program in thyroid epithelial cells [5]. Recently, we demon-
strated that preoperative blood neutrophil-to-lymphocyte
ratio, a surrogate marker for systemic inflammation, corre-
lated with tumor size in differentiated thyroid cancer [6]. In
this context, it remains controversial whether the inflamma-
tion is the cause or consequence in the tumorigenesis of
thyroid cancer.
Human cytomegalovirus (CMV) is a member of the
Herpesviridae family of viruses. Patients with CMV infec-
tion have variable clinical manifestations, from no disease
in healthy hosts to congenital CMV syndrome in neonates
[7]. Meningoencephalitis, retinitis, pneumonitis, myocar-
ditis, hepatitis, enterocolitis, and disseminated disease may
be seen in immunocompromised patients and transplantLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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asymptomatic in immunocompetent persons, CMV estab-
lishes latency and persists in its host. CMV seroprevalence
increases with age. In most studies, seroprevalence reached
60% or more in individuals older than 50 years [8]. Re-
cently, a new entity of infection, called “microinfection”,
has been used to describe the low levels of CMV infection
found in inflammatory diseases and certain cancers [9].
Through mechanisms involving oncogenic transformation,
oncomodulation, and tumor cell immune evasion, CMV in-
fection has been implicated in several cancer types [10]. It
has been shown that CMV infection may induce a prosur-
vival state of latently infected cells via activation of the
MAPK signaling pathway [11].
Sensitive techniques have been developed to detect the
presence of CMV genome or antigens in specific tissues.
In a small series, CMV was the only virus present in thy-
roid tumors [12]. In another study examining herpes
virus tissue distribution, CMV was detected in the thy-
roid gland in three of the eight autopsies [13]. These
findings indicate that the thyroid gland is one of the res-
ervoirs of latent human CMV infection. Considering that
the MAPK pathway is the most common genetic alter-
ation in thyroid cancer and may be activated by CMV
infection, we hypothesized that CMV infection may be
involved in the pathogenesis of thyroid cancer. In the
present study, we set out to examine the viral DNA and
protein in papillary thyroid cancer tissues, and to correl-
ate with the status of tumor BRAF mutation.
Methods
Clinical samples
Tissue samples were collected under an institutional review
board-approved (Mackay Memorial Hospital 12MMHIS175)
tissue procurement protocol after written informed consent
was obtained. A total of 40 patients undergoing total
thyroidectomy for papillary thyroid cancer and 5 patients
undergoing lobectomy for follicular adenoma were included
in this study. Tumor tissues from the center of the lesions
and corresponding normal thyroid tissues from the contra-
lateral lobes of the same patients were obtained. All tumor
tissue samples were carefully dissected to exclude surround-
ing normal tissue. Tissue samples were snap frozen immedi-
ately in liquid nitrogen and stored at −80°C. The tissue
diagnosis was confirmed by frozen sections.
DNA extraction
DNA was extracted from frozen tumor tissues using the
QIAamp DNA mini kit (Qiagen, Valencia, CA, USA) ac-
cording to the manufacturer’s instructions. The quality of
extracted DNA was examined by agarose gel electrophor-
esis. DNA concentrations were determined from the ab-
sorption at 260 nm. The ratio of the absorption at 260 nm
to that at 280 nm was greater than 1.84 in all samples.Direct sequencing analysis of BRAF mutation
A fragment of 228-bp length including codon 600 of
BRAF (RefSeq DNA: NM_004333) was amplified using
the forward primer 5′-TGCTTGCTCTGATAGGAAA
ATG-3′ and the reverse primer 5′-AGCATCTCAGGGC
CAAAAAT-3′. The PCR was run under standard buffer
conditions as follows: 95°C for 5 minutes for one cycle;
45 cycles with denaturing at 95°C for 30 seconds, anneal-
ing at 58°C for 30 seconds, and extension at 72°C for
30 seconds. This was followed by a final extension at 72°C
for 7 minutes. Amplified fragments were separated on a
2% agarose gel and visualized by ethidium bromide stain-
ing. The PCR products were column purified and sub-
jected to sequencing reaction using the forward primer
and BigDye terminator V3.1 cycle sequencing reagents
(Applied Biosystems, Life Technologies, Carlsbad, CA,
USA). Cycling conditions were 95°C for 5 minutes for one
cycle and 95°C for 30 seconds, 55°C for 30 seconds, and
60°C for 1 minute for 45 cycles. DNA sequence was read
on an ABI PRISM 3730xL DNA analyzer (Applied Biosys-
tems), and the BRAF mutations were identified.
Conventional PCR using custom-made primer
To determine whether viral DNA was present in the
tumor samples, frozen tumor tissue specimens were ex-
amined with PCR. DNA was amplified by PCR primers
specific to the CMV UL123 open reading frame (forward
5′-CGACGTTCCTGCAGACTATG-3′ and reverse 5′-
TCCTCGGTCACTTGTTCAAA-3′) [14]. The expected
PCR product would be 117 bp. PCR was performed in
25-μL reaction mixtures that were run for 40 cycles.
PCR products were separated by electrophoresis, and
amplified products were visualized on agarose gels with
ethidium bromide.
Real-time PCR assay
The artus CMV TM assay (Qiagen) targets a 105-bp re-
gion of the major immediate-early (IE) antigen. The
real-time PCR was performed according to the manufac-
turer’s instructions. Briefly, 20 μL of processed sample
were added to a working master mix, which contained
25 μL CMV TM Master, 5 μL CMV Mg-Sol, and 2 μL of
CMV internal control to monitor any possible amplifica-
tion inhibitors. The mixed solution was sealed with an
optical adhesive film, briefly centrifuged, and amplified
using the 7500 Fast Real-Time PCR System (Applied
Biosystems). Cycling parameters were 95°C for 10 mi-
nutes, 45 cycles of 95°C for 15 seconds, and 55°C for
1 minute. Quantitation standards (10, 100, 1,000, and
10,000 CMV DNA copies/μL) included in the supplied
kit were used to generate a standard curve in each run,
allowing determination of the CMV viral load. Results
were analyzed using 7500 System Sequence Detection
Software version 1.4. According to the manufacturer, this
Table 1 Clinical characteristics of the study cohort
Features Number (%)
Number of patients 45
Sex (male/female) 12/33
Age (mean ± SD), years 45 ± 14 (24–81)
Papillary thyroid cancer 40
Tumor size (mean ± SD), cm 2.9 ± 1.1 (0.8–5.2)
Extrathyroidal invasion 28 (70%)
Multifocality 16 (40%)
Lymph node metastasis 25 (63%)
TNM stage
Stage 1 24 (60%)
Stage 2 1 (3%)
Stage 3 9 (23%)
Stage 4 6 (15%)
Follicular adenoma 5
Table 2 Correlation of BRAF mutation with







Female 23 (74%) 5 (56%) 0.411
Age (years) 46 ± 15 40 ± 7 0.437
Hashimoto’s thyroiditis 4 (13%) 2 (22%) 0.602
Body mass index (kg/m2) 25.1 ± 4.2 22.8 ± 1.3 0.482
Body weight (kg) 62 ± 13 62 ± 1 0.725
Tumor size (cm) 3.1 ± 0.9 2.1 ± 1.2 0.045*
Extrathyroidal invasion 25 (81%) 3 (33%) 0.012*
Multifocality 11 (35%) 5 (56%) 0.441
Lymphovascular invasion 9 (29%) 2 (22%) 1.000
Lymph node metastasis 23 (74%) 2 (22%) 0.008*
TNM stage 0.044*
Stage 1 16 (52%) 8 (89%)
Stage 2 1 (3%) 0 (0%)
Stage 3 8 (26%) 1 (11%)
Stage 4 6 (19%) 0 (0%)
*P value <0.05.
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(95% probability that 0.20 copies/μL will be detected).
Western blot analysis
Tissue lysates were prepared by treatment with lysis buffer
as described previously [15]. Lysates were sonicated for
30 seconds on ice and centrifuged at 14,000 × g for 10 mi-
nutes at 4°C. Protein concentration was measured using the
Bradford assay (Bio-Rad Laboratories, Hercules, CA, USA).
For Western blotting, 50 μg of total protein were separated
by electrophoresis on 10% sodium dodecyl sulfate poly-
acrylamide gels. Fractionated proteins were transferred to a
nitrocellulose membrane, and the transfer was controlled
by Ponceau staining. After transfer, the membrane was
blocked with 5% skimmed milk for 30 minutes at room
temperature. The proteins were probed with antibodies
against CMV IE1-72 (MAB810R; Millipore, Billerica, MA,
USA) and β-actin (Sigma, St. Louis, MO, USA) at 4°C
overnight. The results were visualized with horseradish
peroxidase-conjugated secondary antibodies (Sigma) and
enhanced chemiluminescence. CMV standard lysate (The
Native Antigen Company, Oxford, UK) was used as the
positive control.
Statistical analysis
Data are expressed as mean ± SD. Fisher’s exact test was
used for comparison of categorical variables. The non-
parametric Mann-Whitney U test was used for analysis
of continuous variables. Significance of trends in stage
distribution was assessed with the Cochran-Armitage
test for trend. All statistical analyses were two-sided, and
a P value <0.05 was considered statistically significant.
Results
Patient characteristics
Tissue samples from 5 follicular adenoma and 40 papil-
lary thyroid cancer were used in this study after confirm-
ation of the tissue diagnosis (Table 1). Patients with
follicular adenoma underwent lobectomy. Patients with
papillary thyroid cancer had total thyroidectomy and
central neck lymph node dissection, with or without lat-
eral neck dissection. The majority (36 out of 40) of papil-
lary thyroid cancer were of classic papillary histotype,
whereas four were follicular variant. Lymph node metasta-
sis was found in 63% of the patients. More than one-third
of the patients had stage III or IV disease. Six patients had
pathologically confirmed Hashimoto’s thyroiditis. Thyroid-
itis did not correlate with tumor stage (P = 0.188).
BRAF mutation of thyroid tumors
BRAF mutation was not identified in any of the follicular
adenomas and corresponding normal parts of papillary
thyroid cancer. About 78% of the papillary thyroid can-
cers harbored the BRAF mutation (Table 2). Half of thecases with follicular variant of papillary thyroid cancer
were positive for BRAF mutation (P = 0.213). Papillary
cancer with BRAF mutation was significantly associated
with a larger tumor size (P = 0.045), extrathyroidal inva-
sion (P = 0.012), lymph node metastasis (P = 0.008), and
a higher TNM stage (P = 0.044). Age was not associated
with BRAF mutation (P = 0.437).
Figure 1 Real-time quantitative PCR amplification and standard curve of CMV DNA copy numbers. Upper panel: Threshold cycle (Ct)
values are obtained from amplification plots which indicate the change in normalized signal for the four standards between cycles 20 and 40 of
the PCR. Ct is the cycle at which fluorescence crosses a threshold value. Lower panel: The standard curve of Ct versus logarithmic DNA copy
number. Correlation coefficient is indicated.
Figure 2 Detection of tissue CMV protein using Western blot.
Protein levels of CMV immediate-early (IE) antigen were measured
by immunoblot analysis in paired papillary thyroid cancer samples
(P, positive control; N, normal; T, tumor).
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Since CMV enters the latent phase after a primary infec-
tion with its DNA incorporated into the host’s genome,
CMV DNA could be found in tissue DNA extracts of
thyroid CMV infection. To investigate whether CMV
DNA was present in the thyroid tissue samples, DNA
extracted from a total of 45 paired tumorous and adja-
cent non-neoplastic specimens were studied. CMV was
not detected by PCR in any of these samples.
Detection of tissue CMV DNA using real-time PCR assay
To confirm our findings, tissue DNA of thyroid samples
was further evaluated using commercial quantitative
real-time PCR tests. As shown in Figure 1, there was a
strong linear relationship between the threshold cycle
(Ct) values and logarithmic DNA inputs. However, no
CMV IE DNA could be detected in all tested tissues of
follicular adenoma and papillary thyroid cancer.
Detection of tissue CMV protein using Western blot
Although no CMV DNA could be found in fresh frozen tis-
sues of follicular adenoma and papillary thyroid cancer, we
further determined whether CMV protein was aberrantlyexpressed in thyroid tumors. In accordance with our afore-
mentioned results, there was no expression of CMV IE
protein in 8 pairs of normal and cancerous thyroid tissues
(Figure 2).
Discussion
The link between chronic inflammation and increased
risk of developing some cancers is well established [16].
In agreement, thyroid cancer is influenced by and modu-
lates inflammation [17]. Hashimoto’s thyroiditis, one of
the most common autoimmune thyroid diseases, is fre-
quently associated with thyroid cancer [18]. Recently, we
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demonstrating an increased risk for the development
of thyroid cancer after a diagnosis of thyroiditis [19].
Thomas et al. [20] examined herpes virus DNA in tissue
samples of 4 multinodular goiter and 18 autoimmune
thyroid disease (Graves’ disease and Hashimoto’s thy-
roiditis). They found that the percentage of the presence
of at least one kind of herpes virus DNA (herpes simplex
virus type 1 and 2, and herpes virus type 6 and 7) is sig-
nificantly higher in autoimmune thyroid disease than in
multinodular goiter (72% vs. 25%). Although the thyroid
gland is one of the CMV reservoirs, CMV DNA was not
detected in these 22 samples. In other studies, compo-
nents of several viruses such as hepatitis C virus, human
parvovirus B19, Coxsackie virus, and herpes virus could be
detected in the thyroid of Hashimoto’s thyroiditis patients
[21]. However, at the present time there is insufficient evi-
dence for the viral hypothesis in Hashimoto’s thyroiditis.
Microorganisms causing chronic inflammation have
become increasingly investigated as possible cancer initi-
ators/promoters. There has been very little consideration
of the potential role of infectious process in the patho-
genesis of thyroid cancer, although inflammation has
been implicated in the development of thyroid cancer.
Herpes simplex virus type 2 was found to be significantly
associated with papillary thyroid cancer and the presence
of lymph node metastases [22]. Furthermore, human
parvovirus B19 has been frequently present in thyroid
tissues of Hashimoto’s thyroiditis and papillary thyroid
cancer [23]. Although the thyroid gland is one of the
CMV reservoirs [12,13], no previous study has examined
the presence of CMV in thyroid cancer. The findings of
this study suggest that CMV infection is unlikely to be
associated with papillary thyroid cancer.
CMV infection often exhibits an altered pattern of IE
protein expression. Such proteins act through highly so-
phisticated mechanisms to facilitate viral production and
to avoid detection and elimination of the virus by the
immune system [9]. Interestingly, BRAF activation is in-
volved in the expression of CMV IE antigen [24]. Sorafe-
nib is a tyrosine kinase inhibitor being used in advanced
iodine-refractory thyroid cancer and is known to inhibit
BRAF kinase phosphorylation in the MAPK pathway
[25]; of note is the fact that sorafenib also inhibits CMV
replication [24]. In our study, about 78% of papillary thy-
roid cancer harbored the BRAF mutation. Larger tumor
size, extrathyroidal invasion, lymph node metastasis, and
more advanced TNM stage were associated with the
BRAF mutation. This is in keeping with the experience
of others [26]. The prevalence of the BRAF mutation in
papillary thyroid cancer varies from 32% to 90% in the
literature [27], depending on detection methods and
histopathological subtypes. Given that the majority of
our patients had classic subtype of papillary thyroidcancer, our positive rate of BRAF mutation (78%) was
compatible to that reported by other endocrine surgery
centers [28].
We recognize some of the limitations of our study.
The number of patients studied was small, and results
obtained from our selected population may not be ex-
trapolated to other populations. In addition, we did not
investigate CMV serological status among our patients.
A previous study has shown that CMV DNA could be
widely distributed in organs of both seropositive and
seronegative healthy individuals [29]. Therefore, we dir-
ectly assayed the presence of the CMV DNA and protein
in the thyroid gland without serological tests.
Conclusions
CMV DNA and protein were not detected in fresh fro-
zen tissues of follicular adenoma and papillary thyroid
cancer, irrespective of the presence or absence of BRAF
mutation. The possible role of CMV in the pathogenesis
of thyroid cancer is not supported by our study.
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